SILVER SPRING
Idvynso cleared for HIV-1 in adults
- Sponsor
- Merck $MRK
- Drug
- Idvynso · doravirine/islatravir
- Indication
- HIV-1 infection in adults
FDA approved Idvynso, a two-drug single-tablet regimen of doravirine and islatravir, for HIV-1 treatment in adults.
What this means
Idvynso is a once-daily pill combining two HIV drugs that block the virus from multiplying by targeting different stages of its replication process. FDA approved Idvynso for adults with HIV-1, making it the first single-tablet regimen with this specific drug combination. This approval gives patients a simpler treatment option that may reduce the number of pills needed to manage their HIV.
Drug Watch — recent news on Idvynso
- Merck (MRK) Following Keytruda Approvals And IDVYNSO Launch Looks Fully Valued - simplywall.st
- Merck, ADAP Crisis Task Force Agree to Expand IDVYNSO Access in HIV - Contagion Live
- Merck's doravirine/islatravir under FDA review for HIV - MSN
- HIV Treatment Idvynso Approval and Clinical Findings - Infectious Disease Special Edition
- Merck expands HIV drug access through state AIDS programs - Stock Titan
Sponsor Watch — recent news on Merck
- The Real Question Buried Inside Merck Stock's Premium Price
- Merck Reportedly Goes To Bat In Takeover Battle. But Genomics Stock Reverses.
- Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move.
- MRK Stock Jumps on FDA Nod for Cholesterol-Lowering Pill
- The First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?